Area Regional Control & Elimination of PRRS: Tools, Process Enhance Success of Managing Disease on Swine Farms

June 15, 2010 09:09 AM
 
According to a panel of leading swine veterinarians and disease researchers at the 2010 World Pork Expo, years of scientific study and on-farm research is paying off with highly effective strategies to help swine producers in their efforts to prevent and control porcine reproductive and respiratory syndrome (PRRS) virus. The consensus of the group: Producers and veterinarians are making a significant difference in controlling PRRS on production farms today.
 
Scott Dee, DVM, Ph.D., Swine Disease Eradication Center at the University of Minnesota, said the development of area regional control and elimination (ARC&E) programs, along with increased understanding of aerosol transmission and developments in air filtration, biosecurity and refined herd diagnostic techniques have proven to be effective in reducing PRRS virus transmission.
 
"In the last five to seven years, the swine industry has made major strides in understanding how PRRS virus spreads; what biosecurity protocols to use to prevent transmission; and how to more accurately diagnose and manage the disease when it occurs,” Dee said. "One of the most recent developments is called area regional control and elimination, which takes a ‘big picture' approach to disease control by calling for collaboration of producers and veterinarians. This process is based on understanding the PRRS status across farms, as well as the risk factors that promote virus spread, to improve disease control within an area or region.”
 
The goal of ARC&E is to first eliminate PRRS virus on farms in low-prevalence and low-density swine areas, along with control of PRRS in high-prevalence, high-density areas. The end result on the farm is to improve pig performance by reducing wild-type virus load in control areas and reducing the long-term risk of those viruses getting back into PRRS elimination areas.
 
Currently, the ARC&E working model that is used for every region includes five phases of completion:
  • Feasibility assessment
  • Pig-related identification
  • Region characterization
  • Design of PRRS elimination or control strategies
  • Execution and monitoring of farm-specific plan
 
"We are exploring the feasibility of implementing this approach in Minnesota and preliminary results are promising,” Dee added.
 
John Waddell, DVM, Sutton Veterinary Clinic, Sutton, Neb., discussed some of the newer biosecurity protocols that are being implemented by producers to proactively minimize the potential points of contact and eliminate the direct and indirect sources of infection. "Using information gained from the Production Animal Disease Risk Assessment Program (PADRAP), which also involves detailed disease and biosecurity assessments from nearly 2,000 swine farms, we've been successful at identifying, benchmarking and indexing those processes that are either effective or ineffective in preventing and controlling the spread of PRRS,” Waddell said.  
 
"Because the risk assessment data is so extensive and detailed, we have a high level of confidence in what protocols work, based on an operation's type of production flow, geography and concentration of production facilities in the area, disease status, vaccination methods, transportation equipment and other variables,” he added. "These types of models help us to manage not only PRRS virus, but also a number of other swine diseases that follow similar routes of transmission and infection.”
 
Jean Paul Cano, DVM, professional services veterinarian with Boehringer Ingelheim Vetmedica, Inc., said that PRRS vaccination plays a critical role in most disease-management protocols to reduce PRRS infections on the farm as part of area regional control.
 
"Research shows the use of vaccine has direct benefit when used to mitigate the clinical consequences of infection and improves the health and performance of pigs,” he said. "In addition, we've learned vaccinations have indirect benefits in reducing the level of virus and virus transmission within vaccinated populations.”
 
Consequently, reducing the level of PRRS virus that can be transmitted within a facility impacts the dynamics of the entire swine production system.
 
"Depending on the type of production facility, PRRS status and other factors, immunizing pigs against the virus, stabilizing the herd or even reducing the level of virus transmitted may help producers achieve their goals,” Cano added. "Mass vaccination intervention in area regional control programs can be one of the complementary tools along with a herd closure strategy; gilt acclimation programs; and appropriate pig flow and biosecurity protocols. Vaccine can provide protection and biologic and economic benefits when PRRS-naïve pigs are placed into high prevalence areas for finishing.”
Dee noted that, thanks to advances in PRRS research and industry tools and processes, swine veterinarians and producers now have enough information to make a difference when it comes to controlling this devastating disease.
 
"The most effective and successful PRRS control and prevention within an area requires a high degree of cooperation, coordination and collaboration within and among production systems in a region,” Dee concluded. "Fortunately, producers have a number of effective tools and processes available today to better help them determine current status, assess PRRS risk, measure and monitor infection status and improve their disease-management decision making.”
 
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
 
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
 
In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21 percent of net sales in its largest business segment, Prescription Medicines, on research and development.
 
For more information, please visit www.bi-vetmedica.com.
Back to news

Comments

 

Rate this News Article:

Spell Check

No comments have been posted to this News Article

Close